Barillé-Nion S - Search Results

1

The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma.

Romagnoli M, Séveno C, Wuillème-Toumi S, Amiot M, Bataille R, Minvielle S, Barillé-Nion S. Romagnoli M, et al. Br J Haematol. 2009 Apr;145(2):180-9. doi: 10.1111/j.1365-2141.2009.07608.x. Epub 2009 Mar 2. Br J Haematol. 2009. PMID: 19298592 Free article.

2

New insights in myeloma-induced osteolysis.

Barillé-Nion S, Bataille R. Barillé-Nion S, et al. Leuk Lymphoma. 2003 Sep;44(9):1463-7. doi: 10.3109/10428190309178765. Leuk Lymphoma. 2003. PMID: 14565645 Review.

3

Advances in biology and therapy of multiple myeloma.

Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G. Barillé-Nion S, et al. Hematology Am Soc Hematol Educ Program. 2003:248-78. Hematology Am Soc Hematol Educ Program. 2003. PMID: 14633785 Review.

4

Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?

Giuliani N, Colla S, Rizzoli V, Barillé-Nion S, Bataille R. Giuliani N, et al. Cancer Res. 2004 Jan 15;64(2):772-3; author reply 774-5. Cancer Res. 2004. PMID: 14744797 No abstract available.

5

The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.

Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, Amiot M, Pellat-Deceunynck C. Bataille R, et al. Haematologica. 2006 Sep;91(9):1234-40. Haematologica. 2006. PMID: 16956823 Review.

6

Significant impact of survivin on myeloma cell growth.

Romagnoli M, Trichet V, David C, Clément M, Moreau P, Bataille R, Barillé-Nion S. Romagnoli M, et al. Leukemia. 2007 May;21(5):1070-8. doi: 10.1038/sj.leu.2404602. Epub 2007 Feb 22. Leukemia. 2007. PMID: 17315024

7

Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.

Romagnoli M, Desplanques G, Maïga S, Legouill S, Dreano M, Bataille R, Barillé-Nion S. Romagnoli M, et al. Clin Cancer Res. 2007 Oct 15;13(20):6010-8. doi: 10.1158/1078-0432.CCR-07-0140. Clin Cancer Res. 2007. PMID: 17947462

8

[Survivin in cancerology : molecular aspects and therapeutic applications].

Romagnoli M, Séveno C, Bataille R, Barillé-Nion S. Romagnoli M, et al. Med Sci (Paris). 2008 Oct;24(10):821-7. doi: 10.1051/medsci/20082410821. Med Sci (Paris). 2008. PMID: 18950577 Free article. Review. French.

9

Impact of XIAP protein levels on the survival of myeloma cells.

Desplanques G, Giuliani N, Delsignore R, Rizzoli V, Bataille R, Barillé-Nion S. Desplanques G, et al. Haematologica. 2009 Jan;94(1):87-93. doi: 10.3324/haematol.13483. Epub 2008 Nov 10. Haematologica. 2009. PMID: 19001278 Free PMC article.

10

Notch2 signaling sensitizes endothelial cells to apoptosis by negatively regulating the key protective molecule survivin.

Quillard T, Devalliere J, Chatelais M, Coulon F, Séveno C, Romagnoli M, Barillé Nion S, Charreau B. Quillard T, et al. PLoS One. 2009 Dec 11;4(12):e8244. doi: 10.1371/journal.pone.0008244. PLoS One. 2009. PMID: 20011512 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters